| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c469d0019d8cc69cc7ab573609f1b16 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-242 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-242
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16 |
| filingDate |
2006-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46ae12af61b22f7c04676f7931681224
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36ceab8182232215ecdbad186fd304cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0a0472eccd5b7329e450f5d3eca6dfd |
| publicationDate |
2008-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1933853-A1 |
| titleOfInvention |
Tissue disruption treatment and composition for use thereof |
| abstract |
The present invention relates to an agent having activities in the treatment of a tissue disruption. In particular the invention relates to a composition comprising an effective amount of an active fraction separated from a mixture of plasma and/or serum and at least one metal, metal ion or metal salt thereof, wherein said mixture has been denatured and has an activity selected from one or more of the group consisting of: a) healing tissue disruptions; b) modulating apoptosis; c) modulating the activity of TNF- ; d) modulating the activity of TNF- R; e) modulating the activity of TACE; and f) modulating the activity of a caspase. |
| priorityDate |
2005-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |